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Lipopolysaccharide (LPS) activates the innate immune
response through the Toll-like receptor 4 (TLR4)MD-2 com-
plex. A synthetic lipid A precursor, lipid IVA, induces an innate
immune response in mice but not in humans. Both TLR4 and
MD-2 are required for the agonist activity of lipid IVA in mice,
with TLR4 interacting through specific surface charges at the
dimerization interface. In this study, we used site-directed
mutagenesis to identify the MD-2 residues that determine lipid
IVA species specificity. A singlemutation ofmurineMD-2 at the
hydrophobic pocket entrance, E122K, substantially reduced the
response to lipid IVA. Combining themurineMD-2 E122Kwith
the murine TLR4 K367E/S386K/R434Q mutations completely
abolished the response to lipid IVA, effectively converting the
murine cellular response to a human-like response. In human
cells, however, simultaneousmutations of K122E, K125L, Y41F,
andR69GonhumanMD-2were required to promote a response
to lipid IVA. Combining the humanMD-2 quadruple mutations
with the human TLR4 E369K/Q436R mutations completely
converted the humanMD-2/humanTLR4 receptor to amurine-
like receptor. Because MD-2 residues 122 and 125 reside at the
dimerization interface near the pocket entrance, surface charge
differences here directly affect receptor dimerization. In com-
parison, residues 42 and 69 reside at the MD-2/TLR4 interac-
tion surface opposite the dimerization interface. Surface charge
differences there likely affect the binding angle and/or rigidity
between MD-2 and TLR4, exerting an indirect influence on
receptor dimerization and activation. Thus, surface charge dif-
ferences at the two MD-2/TLR4 interfaces determine the spe-
cies-specific activation of lipid IVA.
Lipopolysaccharide (LPS), also known as endotoxin, acti-
vates the innate immune response during Gram-negative bac-
terial infection. Lipid A, the active component of LPS, anchors
LPS to the outer leaflet of the outer membrane of Gram-nega-
tive bacteria. When bacteria divide or die, LPS released into
local tissue or the circulation can trigger innate immune recog-
nition (1). LipidA frommost species is highly proinflammatory,
although certain lipid A molecules and precursors lack stimu-
latory power. The synthetic precursor of Escherichia coli lipid
A, tetraacylated lipid IVA (2) (compound 406), is an agonist in
murine cells and a partial agonist in equine cells but is an antag-
onist in human cells (3).
The Toll-like receptor 4 (TLR4)2 and MD-2 complex con-
stitute the essential components of a receptor system for LPS
(4, 5). CD14, initially believed to be the LPS receptor, is an
enhancing component of the LPS receptor (6). The lack of a
transmembrane or an intracellular signaling domain led to
speculation about an additional LPS receptor component that
actually transduces the LPS signal. TLR4 was identified as the
signaling component of the LPS receptor, based on positional
cloning in mice that fail to respond to LPS (4, 7) and on the
finding that TLR4 knock-out cells did not respond to LPS (8).
The co-receptor MD-2 is essential for LPS recognition (5), and
a single MD-2 point mutation that replaces cysteine 95 with
tyrosine (C95Y) completely abolishes LPS responsiveness (9).
MD-2 knock-out mice, like TLR4 knock-outs, do not respond
to LPS (10). A deficiency in either TLR4 orMD-2 abrogates LPS
signaling, whereas a deficiency in CD14 leads to a 100–1000-
fold decrease in LPS sensitivity formost proinflammatory genes
(e.g. TNF- and IL1) and the apparent abolishment of
response for others (e.g. IP-10) (11) but does not abolish LPS
signaling. The loss of CD14 therefore differs from the loss of
TLR4 or MD-2 in that the presence of CD14 sensitizes cells to
the presence of LPS whereas TLR4 or MD-2 are absolutely
required for LPS responses.
The co-crystal structure of the human TLR4MD-2LPS
complex revealed that LPS binds toMD-2 through the LPS acyl
chains and the MD-2 hydrophobic pocket (12). Five of the six
acyl chains are buried inside the hydrophobic pocket. The sixth
lies on the surface above the hydrophobic pocket and, along
with the MD-2 Phe-126 and Met-85 loops, interacts with the
hydrophobic residues on the C-terminal -strands (18–21)
of TLR4 tomediate dimer:dimer assembly of two LPS-liganded
TLR4MD-2 complexes (note: to facilitate an understanding of
the data shown in this report, the TLR4, MD-2, LPS molecules
in the second TLR4MD-2LPS complex will be labeled as
TLR4, MD-2, LPS). Hydrogen bonds and ionic interactions
are found at the dimerization interface between TLR4, MD-2,
and LPS in the co-crystal structure. Surprisingly, the LPS core
polysaccharide, which is not required to induce a proinflamma-
tory response, also interacts extensively with TLR4 in the co-
crystal structure. Studies with site-directed mutagenesis con-
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firmed that Phe-126 on human MD-2 (hMD-2) is essential for
receptor dimerization (13) and demonstrated that hydrophobic
residues on hMD-2 and human TLR4 (hTLR4) are required for
receptor activation (14).
We previously demonstrated that ionic interactions at the
dimerization interface play an essential role in lipid IVA activa-
tion (15). Mouse TLR4 (mTLR4) is required for the species-
specific activation of lipid IVA because, in the presence of
mouse MD-2 (mMD-2), one phosphate on lipid IVA can inter-
act with a positively charged patch on the opposing mTLR4 (at
the dimerization interface) to trigger dimerization. This posi-
tively charged patch on mTLR4 is replaced with a negatively
charged patch onhTLR4,with the result that humanTLR4does
not respond to lipid IVA (15).
In this study, we used site-directed mutagenesis to swap sur-
face charges between human and mouse MD-2 to identify res-
idues onMD-2 that account for lipid IVA species specificity.We
produced five mutations in both murine and human MD-2 at
residues 42, 69, 58, 122, and 125 designed to swap surface
charges between the two species.We then tested whether these
charge changes interconverted the human and mouse pheno-
typic responses to lipid IVA.We found that the E122Kmutation
was sufficient to abrogate the lipid IVA response by murine
MD-2 but that the K122E mutation alone was not sufficient to
induce a response by humanMD-2; simultaneous mutations of
K125L, R69G, and Y42F also were required for an hMD-2
response. Furthermore, when the hMD-2 quadruple mutant
was introduced toHEK293 cells with the hTLR4 E369K/Q436R
double mutant, a full lipid IVA response was observed, indicat-
ing that the hTLR4hMD-2 receptor has been converted to a
mouse phenotype after these mutations. Conversely, lipid IVA
inhibited LPS responses when the mMD-2 E122K mutant was
introduced to HEK293 cells with the mTLR4 K367E/S386K/
R434Qmutant, suggesting a conversion of themurine receptor
to a human phenotype after these mutations. Thus, unique
MD-2 surface charges at the twoMD-2/TLR4 interfaces deter-
mine the role of MD-2 in lipid IVA activation.
EXPERIMENTAL PROCEDURES
Mutagenesis and Luciferase Assay—Synthetic lipid IVAwas a
gift from Dr. Shoichi Kusumoto (Osaka University, Osaka,
Japan). LPS from E. coli strain O111:B4 (Sigma) was repurified
by a repeat phenol-chloroform extraction (16). The wild type
(WT) hMD-2 and mMD-2 constructs in pEFBOS vector (a
gift of Dr. Kensuke Miyake, Saga Medical School, Nabeshima,
Japan) were used as the PCR template for QuikChange site-
directed mutagenesis under the manufacturer’s instruction
(Stratagene). The hMD-2 mutants that contain one or more of
the fivemutations, F42Y,N58K,G69R, E122K, andL125K,were
engineered from the hMD-2 WT construct, and the mMD-2
mutants that contain one or more of the five mutations, Y42F,
K58N, R69G, K122E, and K125L were engineered from the
mMD-2 WT construct. All mutations were verified by DNA
sequencing (Genewiz, Inc., South Plainfield, NJ).
The effects of thesemutations on LPS and lipid IVA signaling
were tested in HEK293 cells by transient transfection. HEK293
cells were plated in 96-well plates at a density of 20,000 cells/
well. The next day, cells were transfected with: (i) one of the
hTLR4YFP constructs (E369K/Q436R, E369K/K388S/Q436R,
or a WT control), or one of the mTLR4YFP constructs (K367E/
R434Q, K367E/S386K/R434Q, or aWT control); (ii) one of the
hMD-2 or mMD-2 mutants; (iii) an NF-B-luciferase plasmid
(17); and (iv) the Renilla-luciferase plasmid. The next day, the
mediumwas changed to fresh completeDMEMwithout serum,
and cells were stimulated with the indicated concentrations of
LPS/lipid IVA. After overnight stimulation, the supernatants
were removed, and firefly-luciferase activity was measured in
cell lysates. Renilla-luciferase was used for normalization.
For inhibition assays inHEK293 cells,HEK293 cellswere plated
as described above and transfected with: (i) one of the mMD-2
mutants (E122K or F42Y/G69R/E122K/L125K) or aWT control;
(ii) one of the mTLR4 mutants (K367E/R434Q or K367E/S386K/
R434Q) or a WT control; (iii) an NF-B-luciferase reporter con-
struct; and (iv) a Renilla-luciferase reporter construct. The next
day, 1000ng/ml lipid IVAwas added to selectedwells, and after 1h
of incubation, 100ng/mlLPSwas added to the experimentalwells.
After overnight stimulation, NF-B-luciferase was measured in
cell lysates as described above. Renilla-luciferase was used to nor-
malize NF-B-luciferase.
RESULTS
Human and Mouse MD-2 Have Different Surface Charges
Near the Entrance of the Hydrophobic Pockets—According to
our previous model of dimeric mTLR4/mMD-2/lipid IVA (Fig.
1) (15), lipid IVA packs shallowly in the mMD-2 hydrophobic
pocket with the diglucosamine backbone tilted toward the Cys-
95–Cys-105 loop opposite the dimerization interface (12, 15).
This position lifts the 4-phosphate of lipid IVA up from the
hydrophobic pocket so that it can interact with the two posi-
tively charged residues, Lys-367 and Arg-434, on the opposing
mTLR4 (Fig. 1) to trigger dimerization. (Residues on the second
FIGURE 1.Dimeric mTLR4mMD-2lipid IVAmodel. A dimeric mTLR4mMD-
2lipid IVA model was produced as described (15). The A patch, B patch, and
the dimerization interface are circled with dashed lines and labeled as A, B,
and D, respectively. The mTLR4, mMD-2, and lipid IVA from the second
mTLR4mMD-2lipid IVA complex are labeled as mTLR4, mMD-2, and lipid
IVA to differentiate these proteins from those of the first mTLR4mMD-2lipid
IVA complex. Residues Arg-434 on the first mTLR4mMD-2 lipid IVA complex,
and Lys-367, Arg-434, Cys-95, and Cys-105 on the second mTLR4mMD-
2lipid IVA complex are labeled. The Cys-95–Cys-105 loops are indicated by
the red arrow and labeled. Color scheme: mTLR4, white ribbon; mMD-2, blue
ribbon; lipid IVA, yellow spheres; mTLR4, blue-white ribbon; mMD-2, purple
ribbon; lipid IVA, green spheres.
Mutagenesis Studies Define Species Specificity of MD-2
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TLR4/MD-2/lipid IVA molecule are designated “”) Because
these two residues are replaced with the negatively charged
Glu-369 and Gln-436 in hTLR4, lipid IVA does not activate
proinflammatory responses when hTLR4 is present. Hence, the
surface charges of TLR4 at the dimerization interface deter-
mine the role of TLR4 in lipid IVA recognition.
Hydrophobic interactions and hydrogen bonds were ob-
served at the dimerization interface of the lipid IVA activation
model (Fig. 2a). However, because of a reduction of two acyl
chains fromhexaacylated LPS to tetraacylated lipid IVA, hydro-
phobic interactions with the acyl chains were reduced at the
dimerization interface in themTLR4/mMD-2/lipid IVAmodel.
As shown in Fig. 2a, only the upper portion of the fourth acyl
chain on lipid IVA was expected to be involved in hydropho-
bic interactions with mMD-2 and mTLR4 at the dimeriza-
tion interface. In comparison, hydrophobic interactions be-
tween mMD-2 and mTLR4 at the dimerization interface in
the mTLR4mMD-2lipid IVA model were expected to be sim-
ilar to those in the hTLR4hMD-2LPS co-crystal structure (12),
because virtually all hydrophobic residues on MD-2 and TLR4
essential for receptor dimerization (13, 14) are conserved
between the two species (12). In addition, mMD-2 has the
hydrophobic Leu-125 in place of Lys-125 in hMD-2 (Fig. 2a),
which likely enhanced hydrophobic interactions between
mMD-2 and mTLR4 at the dimerization interface. Similarly,
hydrogen bonds betweenArg-434 onmTLR4 and the hydroxyl
group on the fourth acyl chain of lipid IVA (Fig. 2a) contributed
to the stabilization of the mTLR4/mMD-2/lipid IVA dimer.
Comparison of the electrostatic surface charges for hMD-2
and mMD-2 (13, 18) revealed differences near the entrance of
the hydrophobic pockets (Fig. 2b). HumanMD-2 has positively
charged Arg-90 and Lys-122 at the hydrophobic pocket en-
trance, whereasmMD-2 has positively chargedArg-90 but neg-
atively charged Glu-122 at the pocket entrance. Human MD-2
has positively charged Lys-125 at the dimerization interface
close to the pocket entrance, whereasmMD-2 has hydrophobic
Leu-125 at this position. A little further away from the pocket
entrance, hMD-2 has positively charged Lys-58 on the 4
strand that has been implicated in lipid IVA discrimination (19),
whereas mMD-2 has negatively charged Asn-58 at this posi-
tion. Because the acyl chains of LPS bind to the MD-2 hydro-
phobic pocket, and the diglucosamine backbone of LPS sits
next to the pocket entrance (12, 13), modifications of MD-2
surface charges at residues 122, 125, and 58 likely affect lipid
binding and directly influence lipid IVA species specificity.
E122K Mutation on mMD-2 Nearly Eliminated Lipid IVA
Responsiveness—To determine whether any of these surface
charge differences alter the response to lipid IVA, we engi-
neered MD-2 mutants that swapped surface charges between
the human and murine analogs. The effects of these mutations
were measured with the luciferase assay.
N58K, E122K and L125K mutants were created by site-di-
rectedmutagenesis fromWTmMD-2 expressed in the pEFBos
vector. These single substitutions from the native mouse resi-
dues to their human counterparts did not affect LPS signaling
(Fig. 3a), suggesting that these mutations did not disrupt the
structural motif essential for LPS signaling. In comparison,
E122K substantially reduced lipid IVA responsiveness (Fig. 3b),
indicating that Glu-122 at the pocket entrance is essential for
mMD-2 to respond to lipid IVA.
Mutations K122E and K125L Increased the Human MD-2
Response to Lipid IVA—We next examined whether E122K was
sufficient to convert hMD-2mTLR4 from a lipid IVA nonre-
sponder toaresponder.ThesinglemutantsK58NandK125Lwere
used as controls, and the effects were measured as described. LPS
responsiveness was not significantly affected by these mutations
(Fig. 3c), indicating that they did not disrupt the structural motif
essential for LPS signaling. Surprisingly, although theK58Nmuta-
tion did not confer lipid IVA responsiveness to hMD-2, theK125L
mutation conferred weak lipid IVA responsiveness to hMD-2. In
contrast, the K122E mutation conferred strong lipid IVA respon-
siveness to hMD-2 (although not to the level of mMD-2). These
data suggest that surface charge differences at residues 122 and
125 participate in lipid IVA discrimination.
Human andMurineMD-2Have Different Surface Charges at
the A Patch That Physically Associates with TLR4 in the Mono-
meric MD-2TLR4 Complex—In the absence of ligand, MD-2
forms a high-affinity complex with TLR4 through interactions
FIGURE 2. Electrostatic surface charges are different between hMD-2 and
mMD-2 near the hydrophobic pocket entrance. a, zoomed-in view of the
dimerization interface of themTLR4/mMD-2/lipid IVAmodel. Molecules and res-
idues from the secondTLR4MD-2lipid IVA complex are labeledwith “” to differ-
entiate fromthoseof the first TLR4MD-2lipid IVA complex.Hydrophobic interac-
tions, hydrogen bonds, and ionic interactions are indicated by dashed lines and
labeled in blue as HI, HB, and II, respectively. The fourth acyl chain of lipid IVA is
labeled as L4. Color scheme: mMD-2, blue ribbon; lipid IVA, yellow sticks; mTLR4,
blue-white ribbon. ResiduesonmTLR4arecolored in redormagentaand labeled;
residues on mMD-2 are colored in green and labeled. The electrostatic surface
chargeswerecalculated forhMD-2andmMD-2 inMolMol (21).b, surfacecharges
near the hydrophobic pocket entrance of hMD-2 (left) andmMD-2 (right). Color
scheme: negatively charged surface, red; positively charged surface, blue; and
noncharged surface,white. Surfaces that differ between hMD-2 andmMD-2 are
circled in yellow and labeled. Selective surfaces that are common between
hMD-2 and mMD-2 are labeled in gray.
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at the A and B patches (Figs. 1 and 4, a and b) (12, 13). The A
patch had more interactions in the human complex (Fig. 4a),
whereas the B patch had more interactions in the mouse com-
plex (Fig. 4b). Because a stable TLR4MD-2 complex is still
observed in the absence of intact B patch interactions (13), the
A patch interactions between MD-2 and TLR4 likely play a
dominant role in the formation of TLR4MD-2 complex. Sur-
face features at the B patch were quite similar between human
and mouse MD-2 (supplemental Fig. 1a) and between human
and mouse TLR4 (supplemental Fig. 1b). It is likely that the
differences are a secondary effect of different A patch interac-
tions between the two species.
A delicate interaction networkwas observed at theApatch of
both the human (Fig. 4c) andmouse (Fig. 4d) TLR4MD-2 com-
plexes in the co-crystal structures (PDB codes 3FXI and 2Z64)
(12, 13). Positive residues Arg-68 and Lys-109, which are con-
served between hMD-2 and mMD-2, were involved in exten-
sive hydrogen bonds and ionic interactions with neighboring
TLR4 residues at the A patch of the human and mouse com-
plexes (Fig. 4, c and d). An extra hydrogen bond was found in
the human complex between the hydroxyl group of Tyr-42 on
hMD-2 and the carboxyl oxygen of Phe-42 on hTLR4 (Fig. 4c).
This hydrogen bond was absent in the mouse complex because
mMD-2 has Phe-42 that lacks the hydroxyl group on the aro-
matic ring (Fig. 4d). Because Tyr-42 resides on the 3 strand of
MD-2 (Fig. 4a), this extra hydrogen bond between hMD-2 and
hTLR4 likely helps to orient the overall conformation of the
human complex. For example, it may modify the tilt angle
and/or rigidity between hMD-2 and hTLR4 to disfavor dimer-
ization so that extra forces are required to trigger dimerization.
Human and murine MD-2 also differ in electrostatic surface
charges at the A patch (Fig. 4e). Aside from positively charged
Arg-68 and Lys-109 present in both species, the hMD-2 surface
also contains positively charged Arg-69 and the amino group of
Tyr-42. In mMD-2, Arg-69 is replaced with the noncharged
Gly-69, andTyr-42 is replacedwith themore hydrophobic Phe-
42, whose amino group does not lie on the surface. Thus,
hMD-2 is more positively charged thanmMD-2 at the A patch.
Consistently, hTLR4 is more negatively charged at the A patch
than mTLR4 (supplemental Fig. 1c). Because A patch interac-
tions betweenMD-2 andTLR4 aremainly ionic (Fig. 4, c and d),
the increased positive charges onhMD-2 likely result in a hMD-
2hTLR4 complex that is more tightly bound at the A patch.
Thus, a major difference between hMD-2 and mMD-2 at the A
patch arises from two residues, 69 and 42, which permit addi-
tional interactionswithin the humanMD-2TLR4 complex that
may affect binding angle and/or rigidity between hMD-2 and
hTLR4 to disfavor dimerization in the absence of strong ago-
nists such as E. coli LPS.
Mutations R69GandY42F IncreasedHumanMD-2Response
to Lipid IVA—To determine whether residues 69 and 42 play a
role in lipid IVA discrimination, we swapped charges at these
residues between hMD-2 andmMD-2 andmeasured the effects
on LPS/lipid IVA stimulation as described. Although the F42Y
and G69R mutations on mMD-2 did not affect LPS (Fig. 5a) or
lipid IVA signaling (Fig. 5b), the reverse mutations (R69G and
Y42F) on hMD-2 substantially increased lipid IVA responsive-
ness (Fig. 5d), indicating that additional interactions at the A
patch resulting from Tyr-42 and Arg-69 impaired lipid IVA
responsiveness. Thus, lipid IVA activation of MD-2 is influ-
enced by interactions at both the dimerization interface and the
oppositeApatch, which physically associatesMD-2withTLR4.
Mutations of Y42F, R69G, K122E, and K125L, in Combina-
tion, Converted the Human MD-2 Nonresponse to Lipid IVA to
the Full Mouse-like Response—To examine whether mutations
at the dimerization interface and the A patch have a cumulative
effect on lipid IVA signaling, we engineered hMD-2 double
mutants that contain pairwise combinations of the five muta-
tions. All mutants retained their ability to respond to LPS
(supplemental Fig. 2a), indicating that the structural motifs
essential for LPS responsiveness are intact in these mutants.
However, the magnitudes of the responses were different:
hMD-2 responded to lipid IVAwith doublemutants containing
either K122E or R69G, but the response was higher in the dou-
ble mutant R69G/K122E (supplemental Fig. 2b). This confirms
that although Y42F andK125L play a role in responding to lipid
IVA, K122E andR69G are required for a complete LPS-mimetic
activity of lipid IVA.
High order mutants that contain three or four of the five
mutations were further engineered by site-directed
mutagenesis. Similar to other hMD-2 mutants, the LPS
responsiveness remained similar after these mutations
(supplemental Fig. 3a), suggesting that these mutations did
not disrupt the structural motif essential for LPS signaling.
However, the lipid IVA responses were dependent on the
FIGURE 3. Glu-122 and Leu-125 on mMD-2 are essential for lipid IVA
responsiveness. HEK293 cells were transiently transfected with: (i) one of
mMD-2 (a and b) or hMD-2 (c and d) single mutants near the hydrophobic
pocket entrance; (ii) mTLR4WT construct; (iii) a NF-B luciferase reporter con-
struct; and (iv) a Renilla-luciferase reporter construct. The next day, cells were
stimulated with 1000 ng/ml, 100 ng/ml, 10 ng/ml, or 0 ng/ml LPS (a and c) or
lipid IVA (b and d) overnight. Supernatants were then removed, and NF-B-
luciferase was measured in cell lysates. The luciferase shown has been nor-
malized by Renilla-luciferase. The data shown are representative of one
experiment that was repeated a total of four times.
Mutagenesis Studies Define Species Specificity of MD-2
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mutation (supplemental Fig. 3b). There was no significant
increase in lipid IVA response to the triple mutants Y42F/
K122E/K125L and K58N/K122E/K125L, which lack the
R69G mutation. However, substantial gain of function was
observed for the triple mutant R69G/K122E/K125L and the
quadruple mutant K58N/R69G/K122E/K125, and the big-
gest increase was observed for the quadruple mutant Y42F/
R69G/K122E/K125L, underscoring the roles of all four
mutations in lipid IVA activation.
TwohMD-2mutants, R69G/K122E andY42F/R69G/K122E/
K125L, were compared directly with theWT hMD-2 construct
for responsiveness to LPS (Fig. 6a) or lipid IVA (Fig. 6b). As the
number of mutations increased,
the responsiveness to lipid IVA in-
creased. Conversely, when the re-
verse mutations were introduced to
mMD-2 in combination, the lipid
IVA responsiveness was reduced
after the G69R/E122K and F42Y/
G69R/E122K/L125K mutations (Fig.
6d), whereas LPS responsiveness
remained unchanged (Fig. 6c). (The
full list of mMD-2 mutants is shown
in Supplemental Figs. 4 and 5.)
These results confirm that the four
residue differences between hMD-2
and mMD-2, i.e. Tyr-42/Phe-42,
Arg-69/Gly-69, Lys-122/Glu-122,
and Lys-125/Leu-125, all contribute
to lipid IVA discrimination.
In summary, by swapping surface
charges between hMD-2 and mMD-
2, we demonstrated that Glu-122 is
required for mMD-2 to respond
to lipid IVA. Therefore, negative
charges conveyed by Glu-122 at the
pocket entrance are essential for
mMD-2 to respond positively to lipid
IVA stimulation. However, gain of
negative charges at the pocket en-
trance alone (from the K122E mu-
tation) are not sufficient to confer full
response to hMD-2 against lipid IVA
stimulation. Gain of hydrophobic
surface from the K125L mutation
near the dimerization surface (12)
and loss of positive charges at the A
patch from the R69G and Y42F
mutations also are required to con-
vert the mTLR4hMD-2 complex
from a lipid IVA nonresponder to a
lipid IVA responder. Thus, interac-
tions at the dimerization interface
and at the A patch that physically
associates MD-2 with TLR4 cumu-
latively determine the role of MD-2
in the species-specific activation of
lipid IVA.
Lipid IVAActivated theMutant hTLR4 (E369K/Q436R)hMD-2
(Y42F/R69G/K122E/K125L) Complex—We previously demon-
strated that, in the presence of mMD-2, hTLR4 gained lipid IVA
responsiveness after the E369K/Q436R mutation or the E369K/
K388S/Q436R mutation (15). To test whether the combined
mutations of hTLR4 and hMD-2 could convert the human LPS
receptor into a mouse phenotype, we co-transfected the hMD-2
mutant (Y42F/R69G/K122E/K125L) with one of the hTLR4
mutants (E369K/Q436R or E369K/K388S/Q436R) andmeasured
activation. The hMD-2 double mutant R69G/K122E was also
included in this experiment because it increased lipid IVA respon-
siveness more than any other single or double mutant.
FIGURE 4. Electrostatic surface charges are different between hMD-2 and mMD-2 at the A patch that
physically associateswith TLR4. Themonomeric TLR4MD-2 complexes subtracted from the co-crystal struc-
tures (PDB codes 2Z64 and 3FXI) (12, 13) are shown in a and b. The hMD-2/hTLR4 interfaces (a) are colored in
green, and themMD-2/mTLR4 interfaces (b) are colored in yellow. TheA andBpatches are circled and labeled as
A and B, respectively, in a and b. The 3, 4, and 7 strands on MD-2 are labeled. Zoomed-in views of the A
patch interactions are shown in c for the human complex, and d for the mouse complex. Residues involved in
MD-2/TLR4 interactions are shown as green sticks in c for the human complex and yellow sticks in d for the
mouse complex. Hydrogenbonds and ionic interactions are shown indashed lines in c andd, with thedistances
labeled. Color scheme: hTLR4, pink ribbon; hMD-2, brown; mTLR4, white ribbon; mMD-2, blue ribbon. The elec-
trostatic surface charges at the A patch are shown in e. Negatively charged surface, red; positively charged
surface, blue; noncharged surface,white. Surfaces that differ between hMD-2 andmMD-2 are circled in yellow,
with the residues labeled in black in e. Surfaces that are common between hMD-2 and mMD-2 are labeled in
gray in e.
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The LPS response in all of the mutant hTLR4hMD-2 com-
plexes was approximately half of the response of the WT
human complex (Fig. 7a), indicating that some surface features
essential for an optimal LPS response were lost in the
hTLR4hMD-2 complexes after these mutations were intro-
duced.However, the lipid IVA response in themutantswas high
and dose-dependent, unlike the WT hTLR4hMD-2 complex
that did not respond to lipid IVA (Fig. 7b). These results suggest
that the charge reversals at the dimerization interface of hTLR4
and the pocket entrance and at the A patch of hMD-2 are suf-
ficient to convert the human LPS receptor response to a mouse
phenotype. All four mutations on hMD-2 must be required
because use of the hMD-2 double mutant (R69G/K122E) along
with the hTLR4 mutant did not restore lipid IVA response.
Thus, the negative surface of hTLR4 at the dimerization inter-
face, and the more positively charged surface on hMD-2 at the
pocket entrance and at the A patch, determine the roles of
hTLR4 and hMD-2 in the species-specific activation of lipid
IVA.
Lipid IVA Inhibited LPS Responses in the Mutant mTLR4
(K367E/S386K/R434Q)mMD-2 (E122K) Complex—As
described above, by grafting positively charged residues
to hTLR4 and negatively charged or noncharged residues
to hMD-2, we converted the hTLR4hMD-2 complex to a
murine phenotype. To examine the converse, we co-trans-
fected mutant mTLR4 constructs (K367E/R434Q or K367E/
S386K/R434Q) with mutant mMD-2 constructs (E122K or
F42Y/G69R/E122K/L125K) and tested the lipid IVA
responsiveness.
LPS activated all combinations of mutant mTLR4mMD-2
complexes (Fig. 8, black bars), indicating that the four
mutant combinations maintained the structural features
required for LPS signaling. In contrast, lipid IVA did not
activate the mutant mTLR4mMD-2 complexes (Fig. 8, open
bars), indicating that the loss of positive charge at the dimer-
ization interface of mTLR4 and the loss of negative charge at
the hydrophobic pocket entrance of mMD-2 prevented the
normal murine lipid IVA response. Furthermore, when lipid
IVA was incubated with the cells prior to LPS stimulation,
lipid IVA blocked LPS signaling (Fig. 8, gray bars). This result
suggests that the charge reversals were sufficient to convert
the mouse receptor to a human phenotype. Thus, positive
charges at the dimerization interface of mTLR4 and negative
charges at the pocket entrance of mMD-2 define the roles of
mTLR4 and mMD-2 in the species-specific activation of
lipid IVA.
FIGURE 5. Human MD-2 gained weak lipid IVA responsiveness after the
Y42F or R69G mutation. HEK293 cells were transiently transfected with: (i)
one of the hMD-2 or mMD-2 single mutant at the A patch; (ii) a WT mTLR4
construct; (iii) a NF-B luciferase reporter construct; and (iv) a Renilla-lucifer-
ase reporter construct. After overnight transfection, cells were stimulated
with 1000 ng/ml, 100 ng/ml, 10 ng/ml, or 0 ng/ml LPS (a and c) or lipid IVA
(b and d). The next day, supernatants were removed, and NF-B-luciferase
activity was measured in cell lysates. The luciferase shown has been normal-
ized by Renilla-luciferase. The data shown are representative of one experi-
ment that was repeated a total of four times.
FIGURE 6. Human MD-2 gained a full lipid IVA response after the com-
binedmutations of Y42F/R69G/K122E/K125L. HEK293 cells were trans-
fected with: (i) one of the following MD-2 constructs, hMD-2 WT, hMD-2
R69G/K122E mutant, hMD-2 Y42F/R69G/K122E/K125L mutant, mMD-2
WT, mMD-2 G69R/E122K mutant, mMD-2 F42Y/G69R/E122K/L125K
mutant; (ii) a mTLR4 WT construct; (iii) a NF-B luciferase reporter con-
struct; and (iv) a Renilla-luciferase reporter construct. After overnight
transfection, cells were stimulated with 1000 ng/ml, 100 ng/ml, 10 ng/ml,
or 0 ng/ml LPS (a and c) or lipid IVA (b and d). The next day, supernatants
were removed, and NF-B-luciferase activity was measured in cell lysates.
The luciferase shown has been normalized by Renilla-luciferase. The data
shown are representative of one experiment that was repeated a total of
four times.
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DISCUSSION
Lipid IVA is an agonist in rodent cells but an antagonist in
human cells (15). BothmTLR4 andmMD-2 are required for the
LPS-mimetic activity of lipid IVA (15). The essential role of
mTLR4 in lipid IVA activation arises from its unique surface
charges at the dimerization interface (15). In this study, we used
site-directedmutagenesis to demonstrate that the species spec-
ificity ofMD-2 recognition of lipid IVA is determined by surface
charge differences at two specific areas: residues 122 and 125
near the hydrophobic pocket entrance, and residues 42 and 69
at the A patch opposite the dimerization interface (Fig. 9).
The roles of residues 122 and 125 in lipid IVA activation
are easy to understand. Because residue 122 resides at the
hydrophobic pocket entrance, its surface charge can directly
influence lipid IVA binding. The side chain of Glu-122 (from
mMD-2) carries strong negative charges that would repulse
the similarly negatively charged phosphate on lipid IVA to
raise the 4-phosphate (Fig. 2a). This change in orientation
would permit ionic interactions between the 4-phosphate
on lipid IVA and the positively charged patch at the mTLR4
dimerization interface to trigger receptor dimerization. When
murine Glu-122 was mutated to its human counterpart Lys-
122, the positively charged side chain of Lys-122 attracted the
negatively charged 4-phosphate on lipid IVA, forcing lipid IVA
down where it could not interact with the positively charged
patch on mTLR4 to trigger dimerization and reducing lipid
FIGURE 8. Lipid IVA inhibits LPS responses in the mutant mTLR4mMD-2
complexes.HEK293 cellswereplatedona96-well plate overnight. Cellswere
then transfected with (i) one of the mMD-2 mutants, E122K or F42Y/G69R/
E122K/L125K; (ii) one of the mTLR4 mutants, K367E/R434Q or K367E/S386K/
R434Q; (iii) an NF-B luciferase reporter construct, and (iv) a Renilla-luciferase
reporter construct. The next day, selectedwells of cellswere incubatedwith 1
g/ml lipid IVA for 1 h. LPS was then added to selected wells at a concentra-
tion of 100 ng/ml. After overnight of stimulation, supernatants were
removed, and NF-B-luciferase was measured in cell lysates. The luciferase
shownhasbeennormalizedbyRenilla-luciferase.Data areone representative
figure of four repeating experiments.
FIGURE 7. Lipid IVA activates the hTLR4 (E369K/Q436R or E369K/K388S/
Q436Rmutant) and hMD-2 (Y42F/R69G/K122E/K125Lmutant) complex.
HEK293 cells were plated on 96-well plate overnight. Cells were then trans-
fectedwith (i) one of the three hMD-2 constructs:WT, R69G/K122E, and Y42F/
R69G/K122E/K125L; (ii) one of the hTLR4 constructs: WT, E369K/Q436R, and
E369K/K388S/Q436R; (iii) an NF-B luciferase reporter construct; and (iv) a
Renilla-luciferase reporter construct. The next day, cells were stimulatedwith
1000 ng/ml, 100 ng/ml, 10 ng/ml, or 0 ng/ml LPS (a) or lipid IVA (b) overnight.
Supernatants were then removed, andNF-B-luciferasewasmeasured in cell
lysates. The luciferase shown has been normalized by Renilla-luciferase. The
data shownare representative of one experiment thatwas repeated a total of
four times.
FIGURE 9. The four key residues onmMD-2, Glu-122, Leu-125, Gly-69 and
Tyr-42, reside at the dimerization interface and the A patch in the
dimeric mTLR4mMD-2lipid IVA model. A dimeric mTLR4mMD-2lipid IVA
model (15) is shown in two perpendicular views. The essential residues, Lys-
367 and Arg-434 on mTLR4, and Glu-122, Leu-125, Gly-69, and Tyr-42 on
mMD-2 are labeled and shown as spheres. The Phe-126 loop is indicated by
theblackarrowand labeled. Phe-41 is labeledaccording to its atomicposition.
Color scheme:mTLR4,white ribbon;mMD-2,blue ribbon; lipid IVA, yellow sticks;
mTLR4, blue-white ribbon; mMD-2, purple ribbon; lipid IVA, green sticks.
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IVA responsiveness. BecauseWT hMD-2 naturally has Lys-122
at this position, lipid IVA does not activate proinflammatory
responses when hMD-2 is present. However, gain of negative
charges at the entrance of the hMD-2 hydrophobic pocket
alone (by K122E mutation) were not sufficient to convert
hMD-2 into a mouse phenotype. Loss of positive charges at the
dimerization interface (K125L mutation), and at the A patch
(R69G and Y41F mutations) (Fig. 9) were also required for a
strong proinflammatory responses to lipid IVA.
Leu-125 likely affects lipid IVA activation through a direct
effect on receptor dimerization (Fig. 9). Leu-125 sits on the
Phe-126 loop, which is essential for receptor dimerization (13,
14). However, Phe-126 does not directly bridge dimerization in
the hTLR4hMD-2LPS co-crystal structure (12); it actually
folds back toward hMD-2 to accommodate the extra acyl chain
of LPS that lies on hMD-2 surface in the co-crystal structure
(12). Extensive hydrophobic interactions are observed among
the extra acyl chain of LPS, hydrophobic residues on hMD-2
(Phe-126, Ile-124, Leu-87,Met-85, and Val-82), and hydropho-
bic residues on hTLR4 (Phe-440, Leu-444, and Phe-463) at
the dimerization interface. Another interpretation, however, is
that hydrophobic residues on MD-2 and TLR4 at the dimer-
ization interface form a hydrophobic pocket to fit in the extra
acyl chain of LPS lying on hMD-2 surface. Whether this extra
acyl chain simply has a volume effect or actually plays a func-
tional role is not known.
This scenario is changed in the case of lipid IVA activation by
the mTLR4mMD-2 complex. Although mTLR4 has the same
hydrophobic residues (Phe-438, Leu-442, and Phe-461) at
the dimerization interface as hTLR4 (Phe-440, Leu-44, and
Fhe-463), mMD-2 has hydrophobic Leu-125 in place of posi-
tively charged Lys-125 on hMD-2, whereas lipid IVA has four
acyl chains instead of six in LPS. Therefore, the hydrophobicity
of the mMD-2 Phe-126 loop is increased, but lipid hydropho-
bicity is decreased. Leu-125 can coordinate with Phe-126 and
Ile-124 on mMD-2 to interact with Met-417, Phe-438, Leu-
442, and Phe-461 on mTLR4 through hydrophobic interac-
tions (Fig. 2a), partially compensating for the reduced hydro-
phobic interactions due to the loss of two acyl chains in lipid
IVA.
The roles of Gly-69 and Phe-41 in lipid IVA activation are
likely to be indirect: these residues reside at the A patch oppo-
site the dimerization interface (Fig. 9) and in the mTLR4
mMD-2 co-crystal structure, neither one is involved directly in
the A patch interaction with mTLR4 (Fig. 4d) (13, 15). How-
ever, Gly-69 and Phe-41 are next to the two positively charged
residues on mMD-2 (Arg-68 and Lys-109) that interact exten-
sively with mTLR4 at the A patch of the mouse complex (Fig.
4d) (13). A similar interaction network was observed between
hMD-2 and hTLR4 at the A patch in the hTLR4hMD-2LPS
co-crystal structure (Fig. 4c) (12). Unlike F41 on mMD-2 that
does not participate in the A patch interaction, Tyr-41 on
hMD-2 is directly involved in hydrogen bonds with Glu-42
from hTLR4. Arg-69, on the other hand, sits next to Arg-68 on
the same loop (Fig. 4c). Because both Arg-69 and Arg-68 are
positively charged, the electrorepulsive forces between them
will force the two side chains apart, pushing Arg-68 closer to
Glu-42 on hTLR4 and freeing room for Tyr-41 on hMD-2 to
interact with Glu-42 on hTLR4 through hydrogen bonds.
Because Tyr-41 resides on a separate loop connected to the 3
strand instead of the 7 strand containing Arg-68, the gain of a
hydrogen bond at this position likely has a global orientation
effect on hMD-2 that requires extra forces to trigger receptor
dimerization. Because lipid IVA has only four acyl chains and
does not have the core polysaccharide, it cannot activate the
LPS receptor in the presence of hMD-2.
In fact, we suspected that the A patch residues on MD-2
would play a role in lipid IVA discrimination because the rela-
tive orientations of hMD-2 and hTLR4 are different in the
inhibitor-bound state (13) and the agonist-bound state (12).
Prior to publication of the hTLR4hMD-2LPS co-crystal struc-
ture (PDB code 3FXI), Lee and co-workers had published the
co-crystal structure of the TV3hMD-2Eritoran complex (PDB
code 2Z65), which has the TLR4-hagfish fusion protein in place
of intact ectodomain of hTLR4 (13). Both hMD-2 and the
N-terminal 200 residues of hTLR4 are present in both crystal
structures. However, when the two co-crystal structures are
aligned on those hTLR4 N-terminal residues, the relative ori-
entations of hMD-2 are different (supplemental Fig. 6). The
hydrophobic pocket of MD-2 is tilted 6.7 Å (8.5°) farther away
from TLR4 in inhibitor-bound TV3hMD-2Eritoran than it is
in agonist-bound hTLR4hMD-2LPS. It is likely that LPS bind-
ing triggered a global orientation event between hMD-2 and
hTLR4 to facilitate receptor dimerization, due to the strong
hydrophobic interactions at the dimerization interface from
the extra acyl chain. Althoughwe cannot exclude the possibility
that the different tilt angles between the two crystal structures
merely result from the replacement of hTLR4 with TV3 in the
inhibitor-bound state, the observation that charge mutation of
the MD-2 A patch affects lipid IVA activation strongly argues
against this possibility.
Lipid IVA is a partial agonist in equine cells (19). However,
similar to human MD-2, equine MD-2 has the positively
charged Arg-122 at the hydrophobic pocket entrance. There-
fore, repulsive forces cannot be generated at the pocket en-
trance betweenArg-122 and the lipid IVA phosphate to lift lipid
IVA up. However, equine MD-2 has Ser-42 instead of murine
Phe-42 or human Tyr-42 at the A patch. This substitution from
aromatic residue to serine removes not only the hydrogen bond
involving the hydroxyl group on Tyr-42 in the human receptor
complex, but also any potential hydrophobic interactions with
the aromatic ring in both human and mouse receptor. Conse-
quently, the relative binding angle/rigidity between equineMD-2
and equine TLR4 could be substantially different from the other
two species. Hence, lipid IVA functions as a partial agonist in the
presence of equine TLR4MD-2 receptor.
A practical application of our finding here, however, is to
extend this knowledge to the understanding of receptor poly-
morphisms. Species-specific recognition of lipid IVA by the
mouse and human TLR4MD-2 receptor can be interpreted as
two extreme cases of receptor polymorphism resulting in either
complete activation or complete inhibition. Charge variation at
a single residue can alter the response to lipid IVA stimulation.
Single nucleotide polymorphisms at TLR4 residues 299 and 399
reportedly decrease the proinflammatory response to LPS stim-
ulation (20). Because these residues do not directly affect recep-
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tor dimerization (supplemental Fig. 7), these single nucleotide
polymorphisms may alter the relative binding angle/rigidity of
the TLR4/MD-2 complex so that receptor dimerization is not
as easily triggered by LPS cross-linking.
In conclusion, we used site-directed mutagenesis studies to
demonstrate that induced changes in the three major forces at
the dimerization interface, ionic interactions, hydrogen bonds,
and hydrophobic interactions, contribute significantly to re-
ceptor function and explain the species specificity of LPS-bind-
ing responses. Different lipid A analogs that vary in acyl chain
length or composition, or phosphate composition of the diglu-
cosamine backbone, likely have different balances among the
stabilizing forces at the dimerization interface that affect recep-
tor dimerization and activation.
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SI Figure legend 
SI Figure 1. The electrostatic surface charges are similar between hMD-2 and 
mMD-2 at the B patch, and between hTLR4 and mTLR4 at both the A and B 
patches. Electrostatic surface charges were calculated for hMD-2, mMD-2, hTLR4, and 
mTLR4 in MolMol (1). Surface charges of hMD-2 (left) and mMD-2 (right) at the B-
patch are shown in (a), surfaces charges of hTLR4 (left) and mTLR4 (right) at the B 
patch are shown in (b), and surfaces charges of hTLR4 (left) and mTLR4 (right) at the A 
patch are shown in (c). The A and B patches are circled and labeled. Red for negatively 
charged surface, blue for positively charged surface, and white for non-charged surface. 
 
SI Figure 2. The hMD-2 double mutant, R69G_K122E, gained most lipid IVA 
responsiveness among all double mutants. HEK293 cells were transiently tranfected 
with: 1) one of the ten hMD-2 double mutants; 2) mTLR4 wild type construct; 3) a NF-
κB-luciferase reporter construct; 4) a renilla-luciferase reporter construct. After overnight 
transfection, cells were stimulated with 1000 ng/ml, 100 ng/ml, 10 ng/ml, or 0 ng/ml of 
LPS  (a) or lipid IVA (b) overnight. Supernatants were then removed, and NF-κB-
luciferase was measured in cell lysates. The luciferase shown has been normalized by 
renilla-luciferase. Data are one representative figure of three replicates. 
 
SI Figure 3. The hMD-2 quadruple mutant, Y42F_R69G_K122E_K125L, gained 
most lipid IVA responsiveness among all mutants. The high-order hMD-2 mutants 
were transiently transfected with wild type mTLR4 and reporter constructs overnight, and 
stimulated with decreasing concentrations of LPS (a) or lipid IVA (b) as described in SI 
Fig. 2.  The next day, supernatants were removed, and NF-κB-luciferase was measured in 
cell lysates. The luciferase shown has been normalized by renilla-luciferase. One 
representative data from three replicates are shown in the figure. 
 
SI Figure 4. The mMD-2 double mutants that contain the E122K mutation lost most 
of the lipid IVA responsiveness. The ten mMD-2 double mutants were transiently 
transfected with mTLR4 to HEK293 cells, along with an NF-κB luciferase reporter 
construct and renilla-luciferase reporter construct. After overnight transfection, cells were 
stimulated with 1000 ng/ml, 100 ng/ml, 10 ng/ml, or 0 ng/ml lipid IVA (a) or LPS (b). 
The next day, supernatants were removed, and NF-κB-luciferase was measured in cell 
lysates. The luciferase shown has been normalized by renilla-luciferase. Data are one 
representative figure of three repeating experiments. 
 
SI Figure 5. The high-order mMD-2 mutants that contain the E122K mutations lost 
most of the lipid IVA responsiveness. The triple and quadruple mutants that contain 
both E122K and L125K mutations were transiently transfected with mTLR4 to HEK293 
cells, along with an NF-κB luciferase reporter construct and renilla-luciferase reporter 
construct. After overnight transfection, cells were stimulated with 1000 ng/ml, 100 ng/ml, 
10 ng/ml, or 0 ng/ml lipid IVA (a) or LPS (b). The next day, supernatants were removed, 
and NF-κB-luciferase was measured in cell lysates. The luciferase shown has been 
normalized by renilla-luciferase. Data are one representative figure of three repeating 
experiments. 
 SI Figure 6. The hydrophobic pocket of hMD-2 is tilted away from TLR4 in the 
Eritoran-bound state vs. the LPS-bound state. The co-crystal structures of TV3/hMD-
2/Eritoran (PDB ID: 2Z65) (2) and hTLR4/hMD-2/LPS (PDB ID: 3FXI) (3) were aligned 
on the N-terminal 200 residues of hTLR4. The tilt angle and distance of hMD-2 in the 
two structures are labeled. Color scheme: hTLR4 in 3FXI (pink), hMD-2 in 3FXI 
(brown); TV3 in 2Z65 (light yellow), hMD-2 in 2Z65 (green). 
 
SI Figure 7. I299 and L399 in the hTLR4/hMD-2/LPS co-crystal structure. The 
hTLR4/hMD-2/LPS co-crystal structure (PDB ID: 3FXI) (3) was shown in two 
perpendicular views. The single polymorphism residues (SNPs) of I299 and L399 are 
shown as black spheres and labeled. Color scheme: hTLR4 (light pink), hMD-2 (hot 
pink), LPS (cyan); hTLR4’ (wheat), hMD-2’ (magenta), LPS’ (green). 
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